<code id='4ED69F067D'></code><style id='4ED69F067D'></style>
    • <acronym id='4ED69F067D'></acronym>
      <center id='4ED69F067D'><center id='4ED69F067D'><tfoot id='4ED69F067D'></tfoot></center><abbr id='4ED69F067D'><dir id='4ED69F067D'><tfoot id='4ED69F067D'></tfoot><noframes id='4ED69F067D'>

    • <optgroup id='4ED69F067D'><strike id='4ED69F067D'><sup id='4ED69F067D'></sup></strike><code id='4ED69F067D'></code></optgroup>
        1. <b id='4ED69F067D'><label id='4ED69F067D'><select id='4ED69F067D'><dt id='4ED69F067D'><span id='4ED69F067D'></span></dt></select></label></b><u id='4ED69F067D'></u>
          <i id='4ED69F067D'><strike id='4ED69F067D'><tt id='4ED69F067D'><pre id='4ED69F067D'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:17191
          George Yancopoulos on the 2024 Breakthrough Summit East stage.
          George Yancopoulos on the 2024 Breakthrough Summit East stage STAT

          George Yancopoulos is in touch with his teenage self.

          After 35 years as head scientist at Regeneron Pharmaceuticals, Yancopoulos has led the development of 12 approved medicines, turning a once-fledgling company into the $100 billion global drugmaker it is today. And you can trace a straight line back to the childhood fascination with science he fostered growing up in Woodside, Queens.

          advertisement

          “My high school science project was about regenerating neurons, and ‘Regeneron’ is a contraction of ‘regenerating neurons,’” Yancopoulos said at the STAT Summit East on Thursday. “In some ways I’m still working on my high school science project.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Affirmative action in medical school literally saved lives
          Affirmative action in medical school literally saved lives

          AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

          read more
          JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK
          JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

          InhonorofJPMWeek,you’rereadingaspecialeditionofourbiotechnewsletter,TheReadout.Tostayontopofthelates

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          How medical schools plan to diversify without affirmative action

          Fromlefttoright,toprow:STAT'sUshaLeeMcFarling;Vanderbilt'sConsueloWilkins;CarolinaReyesofUCDavisHeal